Archived explainer. For the current picture see today's NUVB page.
NUVATION BIO INC A A (NUVB) is up +6.98% in the latest session. Our newswire has captured 3 stories on NUVB across 3 sources in the last 36 hours, with AI sentiment reading bullish (avg 68/100).
NUVB stock is up 6.98% at $6.21 on Monday, driven by positive updated Phase 2 data for its drug safusidenib in treating IDH1-mutant glioma. The results showed a confirmed objective response rate of 52% and no new safety signals, prompting the expansion of the clinical program into two new studies. Analyst coverage from RBC Capital and Truist Securities has also reinforced investor optimism.
Nuvation Bio announced updated Phase 2 data for safusidenib, showing strong long-term efficacy and safety in grade 2 IDH1-mutant glioma patients. The drug demonstrated a 52% confirmed objective response rate, with only one responder progressing among 27 Japanese patients after a median of 38.8 months. These results have led to the initiation of two new clinical studies to explore the drug's potential in a broader spectrum of IDH1-mutant glioma. RBC Capital analyst Leonid Timashev highlighted the data as reinforcing safusidenib’s competitive profile, estimating a $3 billion opportunity in the space.
Truist Securities raised its price target to $13, while RBC Capital maintained an Outperform rating but lowered its price target to $19. The news has drawn attention from multiple outlets, including Stocktwits News and MarketChameleon, which emphasized the significance of the data and the new clinical trials.
The stock opened at $5.76, slightly below the previous close of $5.80, but quickly reversed to reach an intraday high of $6.52. Trading volume has reached 9.0 million shares, 1.7 times the 3-month daily average. The stock has traded between $2.18 and $9.75 over the past 52 weeks and is currently priced at $6.20. The 30-day average sentiment has improved from 42 to 64 over the last seven days. Recent insider transactions include three sales totaling $1.4 million, with no new buys reported in the last 90 days.
Nuvation Bio has not scheduled earnings in the near term. Investors should monitor the breadth of analyst coverage and any further developments from the expanded clinical trials of safusidenib.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
According to TheFly, RBC Capital analyst Leonid Timashev said the updated long-term follow-up data reinforce safusidenib's competitive profile in IDH1-mutant glioma.
Nuvation Bio announces impressive long-term efficacy and safety data for safusidenib in grade 2 IDH1-mutant glioma, supporting the launch of two new clinical studies. A confirmed objective response rate of 52% and 36-month PFS of 79% highlight the drug’s potential in treating these challenging brain tumors.
Only one responder later progressed among 27 Japanese patients after median 38.8 months; no new safety signals were identified. Two trials will broaden testing.
More on NUVB: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier NUVB move explainers: 2026-07-21 · 2026-07-20